NeOnc Technologies (Nasdaq: NTHI) Announces AI-Driven Findings Showing Ultrasound Enhances the Potency of an Already Effective NEO100 in Treating Primary and Metastatic Brain Tumors

Core Insights - NeOnc Technologies Holdings, Inc. announced preclinical findings indicating that ultrasound enhances the therapeutic potency of NEO100, showing strong antitumor effects across various brain tumor types [1][3] Group 1: Research and Development - The study conducted at the University of Southern California (USC) utilized an AI-driven, 3D-bioprinted New Approach Methodology (NAM) to identify NEO100 as a leading sonodynamic therapy agent [2] - The NAM platform, based on NTHI-patented rapid magnetic 3D bioprinting technology, allows for the quick generation of patient-derived tumor organoids, significantly accelerating biomedical research [2] - An AI-driven neural network was employed to predict compounds likely to respond to focused ultrasound, with NEO100 consistently identified as a leading sonosensitizer [3] Group 2: Clinical Implications - Validation studies on bioprinted tumor spheroids demonstrated that NEO100, when combined with focused ultrasound, exhibited enhanced tumor-killing activity across various brain tumors, supporting its advancement into future clinical trials [3] - The integration of AI, 3D bioprinting, and ultrasound expands NEO100's commercial and clinical opportunities beyond current indications, as stated by the Executive Chairman of NTHI [4] Group 3: Company Overview - NeOnc Technologies Holdings, Inc. focuses on developing therapeutics for central nervous system cancers, with a drug development platform that includes NEO100 and NEO212, both in Phase II clinical trials [5] - The company has a patent portfolio extending to 2038, covering various drug candidates and delivery methods aimed at overcoming the blood-brain barrier [5]